Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib

PURPOSE: The association between initial molecular response and longer-term outcomes with nilotinib was examined. PATIENTS AND METHODS: Patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase from the phase II nilotinib registration study with available postbaseline...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Branford, Susan, Kim, Dong-Wook, Soverini, Simona, Haque, Ariful, Shou, Yaping, Woodman, Richard C., Kantarjian, Hagop M., Martinelli, Giovanni, Radich, Jerald P., Saglio, Giuseppe, Hochhaus, Andreas, Hughes, Timothy P., Müller, Martin C.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2012
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979159/
https://ncbi.nlm.nih.gov/pubmed/23109697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.5217
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki